| Residential College | false |
| Status | 已發表Published |
| Wuling capsule for major depressive disorder: A meta-analysis of randomised controlled trials | |
Zheng W.3; Zhang Y.F.1; Zhong H.Q.3; Mai S.M.3; Yang X.H.3; Xiang Y.T.3
| |
| 2016-09-01 | |
| Source Publication | East Asian Archives of Psychiatry
 |
| ISSN | 22247041 20789947 |
| Volume | 26Issue:3Pages:87-97 |
| Abstract | Introduction: In China, Wuling capsule, a traditional Chinese medicine consisting of Wuling mycelia of Xylaria nigripes (Kl.) Sacc (a rare type of fungus), is used to treat major depressive disorders. A metaanalysis of randomised controlled trials was performed to compare the efficacy and safety of Wuling capsule alone with Wuling capsule-antidepressant combination in the treatment of major depressive disorders. Methods: Two assessors independently selected studies, extracted data, and conducted quality assessment and data synthesis. Standard mean difference, risk ratio (RR) ± 95% confidence interval (CI), the number needed to treat, and the number needed to harm were analysed. Results: A total of 12 randomised controlled trials (880 patients; mean age ± standard deviation, 39.7 ± 12.5 years; male patients, 41 %) were identified, including 4 trials with Wuling capsule alone (n = 340) and 8 with Wuling capsule-antidepressant (sertraline, mianserin, mirtazapine, and paroxetine) combination (n = 540). The mean length of trial was 5.7 ± 1.3 weeks. Meta-analysis of symptomatic improvement at last-observation endpoint and study-defined response and remission revealed no significant differences between the Wuling capsule alone and antidepressant monotherapy. The Wuling capsule-antidepressant cotreatment was superior to antidepressant monotherapy in symptomatic improvement at last-observation endpoint (standard mean difference: -0.46, p = 0.001) as well as study-defined response (68.4% vs. 56.0%, RR = 1.23; p = 0.03) and remission (46.5% vs. 34.5%, RR = 1.35; p = 0.05). Wuling capsule was associated with fewer adverse drug reactions than antidepressant monotherapy. Conclusions: Adjunctive Wuling capsule may augment the effects of antidepressants and may be associated with fewer adverse drug reactions. More large-scale and rigorously designed randomised controlled trials with large sample size are warranted to clarify the effectiveness of Wuling capsule for major depressive disorders. |
| Keyword | Antidepressive agents Depressive disorder major Drugs Chinese herbal |
| URL | View the original |
| Language | 英語English |
| Fulltext Access | |
| Document Type | Journal article |
| Collection | Faculty of Health Sciences |
| Affiliation | 1.National Clinical Research Center for Geriatric Disorders 2.Beijing An Ding Hospital, Capital Medical University 3.Guangzhou Medical University 4.Capital Medical University, Beijing Institute For Brain Disorders 5.Universidade de Macau |
| Recommended Citation GB/T 7714 | Zheng W.,Zhang Y.F.,Zhong H.Q.,et al. Wuling capsule for major depressive disorder: A meta-analysis of randomised controlled trials[J]. East Asian Archives of Psychiatry, 2016, 26(3), 87-97. |
| APA | Zheng W.., Zhang Y.F.., Zhong H.Q.., Mai S.M.., Yang X.H.., & Xiang Y.T. (2016). Wuling capsule for major depressive disorder: A meta-analysis of randomised controlled trials. East Asian Archives of Psychiatry, 26(3), 87-97. |
| MLA | Zheng W.,et al."Wuling capsule for major depressive disorder: A meta-analysis of randomised controlled trials".East Asian Archives of Psychiatry 26.3(2016):87-97. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment